(Q34459356)

2 August 2017

1 reference

title

Current uses and future hopes for clinical pharmacology in the management of HIV infection (English)

1 reference

2 August 2017

1 reference

Back D

1

1 reference

2 August 2017

Khoo S

series ordinal

2

1 reference

2 August 2017

Maher B

series ordinal

3

1 reference

2 August 2017

Gibbons S

series ordinal

4

1 reference

2 August 2017

1 July 2000

1 reference

2 August 2017

1 reference

2 August 2017

1 Suppl 2

1 reference

2 August 2017

12-17

1 reference

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

2 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2000.00001.X

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2000.00001.X

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2000.00001.X

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2000.00001.X

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2000.00001.X

Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2000.00001.X

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2000.00001.X

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2000.00001.X

Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2000.00001.X

10.1046/J.1468-1293.2000.00001.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference